ConSynance Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming breakthrough scientific discoveries into life‐changing therapies for people affected by rare central nervous system (CNS) disorders.

​

Our current focus is on neuropsychiatric conditions associated with dysregulation of the neurotransmitters serotonin, dopamine, and norepinephrine. We are specifically working to address both behavioral dysregulation and hyperphagia in Prader‐Willi Syndrome and related disorders with CSTI-500, a “tunable” triple monoamine reuptake inhibitor. By targeting these debilitating conditions, which have especially high unmet need, we strive to develop innovative therapies that address the unique needs of each patient.